Alberts D S, Mason-Liddil N, O'Toole R V, Abbott T M, Kronmal R, Hilgers R D, Surwit E A, Eyre H J, Baker L H
Arizona Cancer Center, Tucson 85724.
Gynecol Oncol. 1989 Jan;32(1):16-21. doi: 10.1016/0090-8258(89)90842-1.
Between 1979 and 1984, 98 patients considered to have stage III epithelial type ovarian cancer and optimal surgical resections (i.e., less than 2 cm residual tumor masses) were randomly assigned to treatment with 2 cm residual tumor masses) were randomly assigned to treatment with doxorubicin + cyclophosphamide + BCG (DC + BCG) vs doxorubicin + cyclophosphamide + cisplatin (DCP) vs. doxorubicin + cyclophosphamide + cisplatin + BCG (DCP + BCG). Seventeen (17%) were considered ineligible on the basis of formal histopathologic review. The pathologically proven complete response rates for DC + BCG, DCP, and DCP + BCG-treated patients were 20, 23, and 41%, respectively, and the median survival durations were 36.8, 48.2, and 57.4 months, respectively. Because of the relatively small sample size, definite conclusions concerning the response or survival impact of adding cisplatin to DC + BCG or BCG to DCP can not be drawn; nevertheless, all three groups of patients experienced prolonged survival durations with approximately 40% of all eligible patients alive at 5 years.
在1979年至1984年期间，98例被认为患有III期上皮型卵巢癌且接受了最佳手术切除（即残留肿瘤肿块小于2厘米）的患者被随机分配接受阿霉素+环磷酰胺+卡介苗（DC + BCG）与阿霉素+环磷酰胺+顺铂（DCP）与阿霉素+环磷酰胺+顺铂+卡介苗（DCP + BCG）治疗。根据正式的组织病理学检查，17例（17%）被认为不符合条件。DC + BCG、DCP和DCP + BCG治疗患者的病理证实完全缓解率分别为20%、23%和41%，中位生存期分别为36.8个月、48.2个月和57.4个月。由于样本量相对较小，无法得出关于在DC + BCG中添加顺铂或在DCP中添加卡介苗对反应或生存影响的确切结论；然而，所有三组患者的生存期均延长，约40%的符合条件患者在5年时仍存活。
